DUNE MEDICARE ApS is a Danish APS based in København Ø, operating in the Manufacture of pharmaceutical preparations sector. Incorporated in 2010, the company has 8 employees and reported a gross profit of -DKK 1.6m in its latest annual filing.
| Gross profit | -1.6M DKK | +39% |
| EBITDA | -2M DKK | -68% |
| Net profit | -4.2M DKK | -116% |
| Total assets | 0.5M DKK | -88% |
| Equity | -16.8M DKK | -33% |
| Employees | 8 | — |
In its most recent annual report (2023), DUNE MEDICARE ApS reported a gross profit of -DKK 1.6m. The figures on this page draw on 5 annual filings covering 2019 to 2023. The bottom line showed a net loss of DKK 4.2m.
At the end of 2023, current assets covered short-term debt 0.2 times.
| Item | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Gross profit | -1,645 | -1,181 | -3,918 | -1,472 | -3,064 |
| Staff expenses | -0 | -0 | -2 | -120 | -19 |
| EBITDA | -1,985 | -1,181 | -3,920 | -2,222 | -3,083 |
| Depreciation & amort. | -7 | -7 | -5 | -1 | -5 |
| EBIT | -1,992 | -1,188 | -3,925 | -2,223 | -3,087 |
| Net financials | -2,193 | 27,786 | -4,789 | -3,695 | -2,933 |
| Profit before tax | -4,186 | 26,598 | -8,714 | -5,918 | -6,020 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | -4,186 | 26,598 | -8,714 | -5,918 | -6,020 |
| Item | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Total assets | 546 | 4,380 | 3,726 | 3,945 | 2,276 |
| Equity | -16,780 | -12,594 | -39,193 | -30,478 | -24,560 |
| Long-term debt | 14,883 | 14,883 | 0 | 0 | 0 |
| Short-term debt | 2,444 | 2,092 | 42,919 | 34,423 | 26,836 |
| Total debt | 17,326 | 16,974 | 42,919 | 34,423 | 26,836 |
28 financial ratios from the latest filing, each graded against companies in the same industry.
Net profit as a percentage of total assets — the return generated on the capital employed.
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA relative to debt — how much operating earnings are available to service the debt.
The ability to pay the interest on the company's debt out of its earnings.
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
The size of this year's increase or decrease in the company's debt.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
The size of this year's increase or decrease in the company's equity.
| Name | Role | Member since |
|---|
LY Chief Executive Officer | Chief Executive Officer | 2023 – 2024 |
JS Chief Executive Officer | Chief Executive Officer | 2021 – 2023 |
JS Chief Executive Officer | Chief Executive Officer | 2010 – 2015 |
EH Chief Executive Officer | Chief Executive Officer | 2010 – 2010 |
AH Liquidator | Liquidator | 2024 – 2024 |
No data on file.
| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Individual | 100% | 100% | 2023 | |
| Company | 100% | 100% | 2010 |
| Person | Role here | Other companies |
|---|---|---|
| Anders Hoffmann Kønigsfeldt | Liquidator | 43 companiesMany roles |
| Jacob Sporon-Fiedler | Chief Executive Officer | 1 company |
| Elise Hellesø Rinvar | Chief Executive Officer | 1 company |